普瑞眼科(301239.SZ):截至目前還沒有體外培育的眼科醫療服務機構
格隆匯5月10日丨普瑞眼科(301239.SZ)於2023年5月9日下午15:00-17:00召開業績説明會,就“公司未來擴張發展採用體外還是體內培育擴張模式,或兩者同時進行?未來公司發展的速度大致在什麼範圍,比如收入和利潤分別保持年複合增速多少?公司體外培育的項目目前有多少個?”,公司表示,公司繼續聚焦主業,緊緊圍繞在全國高線城市,按照“全國連鎖化+同城一體化”的佈局戰略,綜合運用多種方式推進醫院擴張計劃。具體安排會及時通過臨時公吿向市場投資者披露。
眼科醫療服務行業的市場需求持續旺盛,行業景氣度較好,公司作為行業內排名前列的機構,也將充分受益於行業的增長。隨着公司實現上市,核心競爭力進一步增強,市場份額將逐步提升。
截至目前,公司還沒有體外培育的眼科醫療服務機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.